Prescription Drug Monitoring Program Best Practices Act of 2018

Bill: 115-hr-6608
Sponsor: full_name: Rep. McSally, Martha [R-AZ-2]
Introduced: 2018-07-26
Policy area: Health
Subjects: Appropriations

Congressional oversight

Drug, alcohol, tobacco use

Government studies and investigations

Health information and medical records

Prescription drugs
Latest action: action_date: 2018-07-27
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2018-07-26
action_desc: Introduced in House
text: <p><b>Prescription Drug Monitoring Program Best Practices Act of 2018</b></p> <p>This bill establishes a series of grant programs to support prescription drug monitoring programs (PDMPs), including a grant program to facilitate the adoption of a specified system that allows PDMP data to be shared across states.</p>

tv_txt: I 115th CONGRESS 2d Session H. R. 6608 IN THE HOUSE OF REPRESENTATIVES July 26, 2018 Ms. McSally (for herself and Mr. Cramer ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for the development and dissemination of best practice guidelines for using data collected by prescription drug monitoring programs to identify drug diversion and abuse, and for other purposes.

1. Short title This Act may be cited as the Prescription Drug Monitoring Program Best Practices Act of 2018 . 2. Best practice guidelines for using data collected by prescription drug monitoring programs (a) Best practice guidelines The Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall— (1) develop best practice guidelines and potential enhancements to facilitate use of and strengthen prescription drug monitoring programs to identify— (A) unlawful diversion or misuse of controlled substances; and (B) the potential for harmful drug interactions; (2) include in such guidelines— (A) data elements that should be included in proactive, unsolicited reports that are generated and disseminated to authorized users to identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends; and (B) best practices on treatment options for consideration by prescribers (or other health care providers) for prescription drug monitoring programs that include data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents; (3) identify potential barriers to implementation of such guidelines and develop recommendations for addressing such barriers (such as development of standard data elements to be included in proactive or unsolicited reports or whether data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents should be included in prescription drug monitoring programs); and (4) not later than 12 months after the date of the enactment of this Act, submit to Congress a report that includes best practices identified and a proposed plan for disseminating and supporting adoption of such best practices by state prescription drug monitoring programs. (b) Input from relevant stakeholders In developing best practice guidelines under subsection (a), the Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall conduct a public workshop and otherwise engage with relevant stakeholders to help inform the development of best practices to— (1) identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends; (2) identify potential data elements to include in proactive, unsolicited reports that are generated and disseminated to authorized users to identify such patients at the highest risk and identify potential inappropriate prescribing trends, and assess whether data on prescriptions for medication assisted treatments for substance use disorder and opioid overdose reversal agents should be incorporated and specific considerations for prescribers based on such information; and (3) identify additional enhancements to prescription drug monitoring programs and potential barriers to adoption and recommendations for addressing such barriers. (c) Grants (1) In general The Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall award grants to States to support adoption of best practices identified under subsection (b). (2) Amount of awards The total amount awarded to any State under this subsection shall be— (A) not less than $25,000; and (B) not more than $50,000. (3) Authorization of appropriations To carry out this subsection, there is authorized to be appropriated $500,000. 3. Transfer of prescription drug monitoring program data across State lines (a) Facilitating adoption of systems by States (1) In general The Director of the Bureau of Justice Assistance shall facilitate the adoption of the PMP InterConnect System of the National Boards of Pharmacy (or another appropriate system for the transfer of prescription drug monitoring program data across State lines) by all States. (2) Grants (A) Award The Secretary may award grants to eligible States for technical assistance in addressing barriers to the adoption of a system described in paragraph (1). (B) Eligibility To be eligible to receive a grant under this paragraph, a State must not have adopted a system described in paragraph (1) as of the date of the grant award. (C) Period The period of a grant under this paragraph shall not exceed 5 years. (D) Amount of awards The total amount awarded to any State under this paragraph shall be— (i) not less than $50,000; and (ii) not more than $100,000. (E) Authorization of appropriations To carry out this paragraph, there is authorized to be appropriated $500,000. (b) GAO study (1) Study The Comptroller General of the United States shall— (A) conduct a study to determine how efficiently and effectively State prescription drug monitoring programs are sharing data pursuant to the PMP InterConnect System of the National Boards of Pharmacy (or other systems); and (B) submit a report to the Congress on the results of such study, including recommendations for the improvement of such sharing. (2) Response by BJA Not later than 180 days after the date on which the report under paragraph (1) is submitted to the Congress, the Director of the Bureau of Justice Assistance shall submit a plan to the Congress for addressing the recommendations in such report. (c) Pilot program for regional sharing of PDMP data (1) In general The Assistant Secretary for Mental Health and Substance Use, in consultation with the Office of the National Coordinator for Health Information Technology, shall facilitate regional sharing across State lines of prescription drug monitoring program data. (2) Grants (A) Awards In carrying out paragraph (1), the Assistant Secretary for Mental Health and Substance Use shall award grants to States (or a collaboration of States) to facilitate such regional sharing. (B) Amount of awards per fiscal year The total amount awarded under this paragraph with respect to any region per fiscal year shall be— (i) not less than $100,000; and (ii) not more than $200,000. (C) Authorization of appropriations To carry out this paragraph, there is authorized to be appropriated $5,000,000.